Login / Signup

Add-on treatment with cenobamate is already effective at low doses in refractory focal epilepsy: A prospective observational study.

Yulia NovitskayaElisa SchützBirgitta MetternichAndreas Schulze-BonhageMartin Hirsch
Published in: Epilepsia (2024)
We found a clinically relevant response to cenobamate already at a low daily dose of 100 mg also in a patient cohort with a higher degree of drug resistance than in pivotal trials. Our prospectively collected data provide real-world evidence for high efficacy and good tolerability of the drug, although no standardized treatment protocol or comparison with a control group was applied.
Keyphrases
  • physical activity
  • emergency department
  • combination therapy
  • big data
  • artificial intelligence
  • deep learning
  • clinical evaluation